Sanofi says next-gen COVID booster shot has potential against main variants – Reuters

Sanofi says next-gen COVID booster shot has potential against main variants – Reuters

Sanofi logo at the company’s headquarters in Paris, France, February 4, 2022. REUTERS/Benoit Tessier/File Photo
PARIS, June 13 (Reuters) – French drugmaker Sanofi (SASY.PA) said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK (GSK.L) showed potential in two trials to protect against the virus’s main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.
While the two companies’ first experimental COVID shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is molded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations.
Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer (22UAy.DE)(PFE.N) and Moderna (MRNA.O).
In a separate trial conducted by a French hospitals network, Sanofi’s Beta-adapted booster shot triggered a higher immune response than Sanofi’s first-generation shot or Pfizer-BioNTech’s established vaccine in previously vaccinated volunteers.
"The Beta variant expresses similar mutations across multiple variants of concern, including Omicron, making it a strong vaccine candidate to confer broad protection against multiple strains of COVID-19," said Thomas Triomphe, the head of Sanofi’s vaccine business.
Highlighting the need for vaccine makers to address new variants of concern in a saturated COVID vaccine market, Valneva (VLS.PA) on Friday said it was in talks to try and salvage a supply agreement that the European Commission cancelled. read more
Valneva’s product is based on the original virus found in the Chinese city of Wuhan, like BioNTech-Pfizer and Moderna’s dominant first-generation shots.
Our Standards: The Thomson Reuters Trust Principles.
Mainland China reported 159 new coronavirus cases for June 18, of which 36 were symptomatic and 123 were asymptomatic, the National Health Commission said on Sunday.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.